Control of nausea and vomiting after chemotherapy: what is the evidence?
- 11 July 2002
- journal article
- review article
- Published by Wiley in Internal Medicine Journal
- Vol. 32 (8) , 401-407
- https://doi.org/10.1046/j.1445-5994.2002.00259.x
Abstract
The control of nausea and vomiting is an important problem for patients undergoing chemotherapy. With the introduction of newer agents, including 5-HT3 antagonists, nausea and vomiting control after chemotherapy has much improved but is not always optimal. While there is an intrinsic limitation to the efficacy of anti-emetic drugs, their efficacy can be further reduced if the drugs are not used appropriately. In some circumstances newer anti-emetics may be unnecessary and better nausea and vomiting control may be established by use of older agents. This paper summarizes current evidence regarding the optimal approach to management of nausea and vomiting in patients undergoing chemotherapy.Keywords
This publication has 43 references indexed in Scilit:
- Dexamethasone Alone or in Combination with Ondansetron for the Prevention of Delayed Nausea and Vomiting Induced by ChemotherapyNew England Journal of Medicine, 2000
- Acupuncture: An Evidence-Based Review of the Clinical LiteratureAnnual Review of Medicine, 2000
- Evidence-based medicine and complementary medicineEvidence-Based Mental Health, 1999
- Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor AntagonistNew England Journal of Medicine, 1999
- Review of Medical Management of Cancer Treatment Induced EmesisJournal of Pediatric Hematology/Oncology, 1998
- 5-HT3 Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and VomitingDrugs, 1998
- Pathophysiology, Severity, Pattern, and Risk Factors for Carboplatin-induced EmesisOncology, 1996
- Participation of Serotonin on Early and Delayed Emesis Induced by Initial and Subsequent Cycles of Cisplatinum‐Based Chemotherapy: Effects of AntiemeticsThe Journal of Clinical Pharmacology, 1993
- Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and FluorouracilNew England Journal of Medicine, 1993
- Ondansetron plus Metopimazine Compared with Ondansetron Alone in Patients Receiving Moderately Emetogenic ChemotherapyNew England Journal of Medicine, 1993